Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
87.59
+1.47 (+1.71%)
Products, Strategic Combinations

Qurient Announces Collaboration Agreement With MSD

Published: 09/14/2022 21:37 GMT
Merck & Co Inc (MRK) - Qurient Announces Collaboration Agreement With Msd to Evaluate Selective Cdk7 Inhibitor Q901 in Combination With Keytruda® (pembrolizumab).
Qurient Co Ltd - Q901 is Ready for Dose Escalation Study in U.S. for Treatment of Selected Advanced Solid Tumors (nct05394103).
Qurient Co Ltd - Phase 1/2 Study of Q901 and Keytruda is Designed to Enroll Patients With Advanced Solid Tumors.
Qurient Co Ltd- Will Conduct a Phase 1/2 Study in U.S. to Evaluate Safety and Efficacy of Q901 in Combination With Keytruda.
Qurient Co Ltd - Terms of Collaboration Were Not Disclosed.